Foo Lisa Y sold $2.6M of THC

Foo Lisa Y (EVP, Chief Operating Officer) sold 10,000 shares of TENET HEALTHCARE CORP (THC) at $258.03 ($2.58M total) on 2026-07-29.

Original reporting
SEC EDGAR · Foo Lisa Y
Published Aug 1, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 1, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale details: 10,000 shares at $258.03, total value $2.58M, with holdings after sale of 32,053 shares, and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 6/10Novelty 4/10Timing: Form 4 filed 2026-07-31, transaction dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare, reporting an open-market sale by the COO.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare COO sold 10,000 shares in an open-market transaction at $258.03 on 2026-07-29, per Form 4 filed 2026-07-31.

Expected impact

Likely limited near-term impact; treat as low-signal unless paired with other disclosures or unusual volume.

Evidence & confidence

The filing discloses transaction size, price, and holdings, but provides no earnings, guidance, investigation, or deal catalyst. Insider sales are common and often non-informational, though the absence of a 10b5-1 plan slightly increases interpretive uncertainty.

Market effects

No clear sector read-through from a single insider sale at one healthcare services company.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could reflect discretionary selling ahead of perceived risk, so some traders may front-run downside if they treat insider behavior as a leading indicator.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Foo Lisa Y

    EVP, Chief Operating Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.